The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel (WP) or eribulin (E) followed by doxorubicin and cyclophosphamide (AC) in women with locally advanced HER2-negative breast cancer (LABC): NSABP FB-9.
Jame Abraham
No relevant relationships to disclose
Andre Robidoux
Honoraria - Eisai Canada; Novartis Canada; Roche Canada
Antoinette R. Tan
Research Funding - Eisai
Marc E. Buyse
Employment or Leadership Position - IDDI
Stock Ownership - IDDI
Norman Wolmark
No relevant relationships to disclose
Samuel A. Jacobs
No relevant relationships to disclose